157 related articles for article (PubMed ID: 3677107)
1. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
[TBL] [Abstract][Full Text] [Related]
2. [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group].
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2425-33. PubMed ID: 3729497
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
4. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
Schilcher RB; Haas CD; Samson MK; Young JD; Baker LH
Cancer Res; 1986 Jun; 46(6):3147-51. PubMed ID: 3698029
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
[TBL] [Abstract][Full Text] [Related]
12. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
13. [Phase I study on oral administration of methyl-6-[[[(2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Kanamaru A; Nagai K; Fujita S; Masaoka T; Takubo T; Kitani T; Taniguchi N; Horiuchi A; Tsubaki K; Kawagoe H; Hirata M; Yonezawa T; Tsubakio T; Yasunaga K; Okamoto Y; Fujitake H; Ohkubo A
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1831-7. PubMed ID: 6882006
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of carboplatin (CBDCA) in children with cancer.
Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
[TBL] [Abstract][Full Text] [Related]
15. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study on MCNU in patients with advanced or recurrent gastrointestinal cancer].
Niimoto M; Yoshinaka K; Hattori T; Kobayashi S; Hosoma S; Ogawa Y; Iwamori S; Nagata N; Yamagata S; Nishimawari K
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1813-9. PubMed ID: 4037810
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
